Dose-Dependent Suppression of Human Glioblastoma Xenograft Growth by Accelerator-Based Boron Neutron Capture Therapy with Simultaneous Use of Two Boron-Containing Compounds
| Autor: | E. L. Zavjalov, Ivan A. Razumov, V. V. Kanygin, Alexander Zaboronok, D. A. Kasatov, Tatiana Sycheva, Sergey Taskaev, A. I. Kichigin, Bryan J. Mathis, Alphiya R. Tsygankova, Tatiana Guselnikova, O. I. Solovieva |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
QH301-705.5
chemistry.chemical_element Biology animal tumor model General Biochemistry Genetics and Molecular Biology Sodium Borocaptate Article medicine Dosimetry Irradiation Biology (General) Boron boronophenylalanine General Immunology and Microbiology accelerator-based neutron source Radiochemistry sodium borocaptate glioblastoma Neutron radiation medicine.disease Neutron capture chemistry boron neutron capture therapy Neutron source General Agricultural and Biological Sciences boron compounds Glioblastoma |
| Zdroj: | Biology Volume 10 Issue 11 Biology, Vol 10, Iss 1124, p 1124 (2021) |
| ISSN: | 2079-7737 |
| DOI: | 10.3390/biology10111124 |
| Popis: | Simple Summary Accelerator-based boron neutron capture therapy (BNCT) has opened up new perspectives in increasing cancer treatment efficacy, including malignant brain tumors and particularly glioblastoma. We studied dosimetry control optimization, neutron beam parameter adjustment, and two boron compound combinations (along with single and double irradiation regimens) to assess safety and increase therapy efficacy, using a U87MG xenotransplant immunodeficient mouse model. In two sets of experiments, we achieved increases in tumor-growth inhibition (to 80–83%), a neutron capture therapy ratio of 2:1 (two times higher neutron capture therapy efficacy than neutron irradiation without boron), and increases in animal life expectancy, from 9 to 107 days, by treatment parameter adjustment. These results will contribute to the development of clinical-trial protocols for accelerator-based BNCT and further innovations in this cancer treatment method. Abstract (1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograft-bearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two 10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|